Collegium Pharmaceutical (COLL) Tax Provisions (2020 - 2026)

Collegium Pharmaceutical's Tax Provisions history runs 7 years deep, the most recent figure standing at $4.2 million for Q1 2026.

• On a quarterly basis, Tax Provisions rose 501.99% year-over-year to $4.2 million in Q1 2026; TTM through Mar 2026 was $33.3 million, a 57.21% increase from a year earlier, with the FY2025 full-year figure at $29.7 million, up 1.26% from the prior year.
• Tax Provisions slipped to $4.2 million in Q1 2026 per COLL's latest filing, from $12.1 million in the prior quarter.
• Across five years, Tax Provisions topped out at $14.8 million in Q4 2023 and bottomed at -$2.8 million in Q1 2022.
• The 5-year median for Tax Provisions is $4.8 million (2023), against an average of $5.1 million.
• Across the five-year window, Tax Provisions slumped 1375.0% in 2022 and surged 6900.76% in 2024, its largest moves.
• Year by year, Tax Provisions stood at -$592000.0 in 2022, then surged by 2594.93% to $14.8 million in 2023, then sank by 67.96% to $4.7 million in 2024, then soared by 155.08% to $12.1 million in 2025, then sank by 64.85% to $4.2 million in 2026.
• Per Business Quant, the three latest COLL Tax Provisions figures stand at $4.2 million (Q1 2026), $12.1 million (Q4 2025), and $11.9 million (Q3 2025).